Form 4: Neurocrine Biosciences Executive David W. Boyer Sells Shares Under 10b5-1 Trading Plan

David W. Boyer, Chief Corporate Affairs Officer of Neurocrine Biosciences, sold 1,295 shares of common stock at $113.66 per share under a pre-arranged 10b5-1 trading plan.

Summary

• On October 3, 2024, David W. Boyer, Chief Corporate Affairs Officer of Neurocrine Biosciences Inc. (NBIX), sold 1,295 shares of common stock.
• The sale was executed at a price of $113.66 per share.
• Following the transaction, Boyer directly owns 377 shares of Neurocrine Biosciences Inc.
• The sale was conducted under a Rule 10b5-1 trading plan adopted on June 14, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale under a pre-arranged trading plan. There's no indication of positive or negative sentiment towards the company's prospects.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure of an insider stock sale. It's common for executives to use 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information. The sale itself doesn't necessarily indicate a negative outlook on the company.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, but it's unlikely to be significant given the relatively small number of shares sold and the existence of the 10b5-1 trading plan.

Key Dates